Compare SGI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGI | ROIV |
|---|---|---|
| Founded | 1846 | 2014 |
| Country | United States | United Kingdom |
| Employees | 19000 | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 20.7B |
| IPO Year | N/A | 2021 |
| Metric | SGI | ROIV |
|---|---|---|
| Price | $74.97 | $27.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $97.88 | $28.94 |
| AVG Volume (30 Days) | 2.7M | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $7.30 | N/A |
| Revenue Next Year | $4.99 | $744.61 |
| P/E Ratio | $48.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $56.15 | $10.58 |
| 52 Week High | $98.56 | $30.33 |
| Indicator | SGI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 44.20 |
| Support Level | $69.62 | $26.94 |
| Resistance Level | $75.69 | $27.94 |
| Average True Range (ATR) | 3.26 | 0.87 |
| MACD | -0.25 | -0.20 |
| Stochastic Oscillator | 5.25 | 16.35 |
Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses Mattress Firm, Tempur Sealy North America and Tempur Sealy International. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.